Press Releases
Integromics and Ingenuity expand their co-operation with the integration of a fourth Integromics product to Ingenuity’s IPA
Integromics, a market leader in IT solutions for life sciences in the field of genomics and proteomics, today announces that it has extended its partnership with Ingenuity(R), a provider of information and analytics solutions for life science researchers. The...
Press Releases
AstraZeneca demonstrates commitment to predictive science at international modelling conference
The 2011 American Conference of Pharmacometrics (ACOP) got underway this weekend with attendees from around the world converging on San Diego, US - including a delegation and dedicated exhibition team from AstraZeneca. Now in...
Press Releases
Oncodesign offers world’s most comprehensive collection of patient-derived colorectal tumor models
Oncodesign announced today that the company has acquired exclusive commercialization rights to distribute the world’s most comprehensive collection of human colorectal cancer models directly developed from patient’s tumors. Oncodesign’s clients can now access the entire collection to evaluate therapeutic...
Press Releases
CIT launches LeadScreen (TM), a new range of fast, cost-effective services for drug candidate selection
CIT, a leading European non-clinical CRO specialized in health and safety research, announces today a new range of fast and economical services to meet the growing needs of companies developing the drugs of tomorrow. The services, grouped under the...
Press Releases
Ken Jones, COO Europe, Astellas joins GSK, Shire, Takeda and Bausch & Lomb on value based selling panel session
With one week to go SFE Europe shows no sign of slowing down. With over 550 confirmed attendees and an a 80% ratio from within industry- it looks like the best networking option for sales and marketing pharmaceutical executives...
Press Releases
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma
Roche announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer. The study...
Press Releases
Novartis completes acquisition of majority stake in Zhejiang Tianyuan
Novartis announced that it completed the transaction to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. This acquisition provides Novartis with an expanded presence in the Chinese vaccines market and is expected...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
